Hsbc Holdings PLC Boosts Stock Position in Dyne Therapeutics, Inc. $DYN

Hsbc Holdings PLC lifted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 112.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,396 shares of the company’s stock after purchasing an additional 15,042 shares during the quarter. Hsbc Holdings PLC’s holdings in Dyne Therapeutics were worth $286,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rhumbline Advisers boosted its holdings in shares of Dyne Therapeutics by 4.2% in the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company’s stock worth $1,398,000 after purchasing an additional 5,383 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company’s stock worth $251,000 after purchasing an additional 2,345 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Dyne Therapeutics by 7.7% in the 4th quarter. Northern Trust Corp now owns 777,013 shares of the company’s stock worth $18,306,000 after purchasing an additional 55,511 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock worth $183,000 after purchasing an additional 1,481 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Dyne Therapeutics by 8.9% in the 1st quarter. Swiss National Bank now owns 118,300 shares of the company’s stock worth $1,237,000 after purchasing an additional 9,700 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox acquired 100,000 shares of the company’s stock in a transaction on Monday, July 14th. The stock was acquired at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the acquisition, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This represents a 70.33% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 14.14% of the company’s stock.

Dyne Therapeutics Trading Down 1.8%

Shares of DYN stock opened at $13.24 on Friday. The stock has a market capitalization of $1.88 billion, a PE ratio of -3.43 and a beta of 1.10. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $37.08. The business has a 50-day moving average of $10.70 and a 200 day moving average of $11.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DYN shares. Robert W. Baird cut their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday, June 18th. Stifel Nicolaus cut their price objective on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, July 31st. Jones Trading began coverage on Dyne Therapeutics in a report on Thursday, June 26th. They issued a “buy” rating and a $30.00 price objective for the company. Oppenheimer dropped their target price on Dyne Therapeutics from $34.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, August 6th. Finally, HC Wainwright dropped their target price on Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Dyne Therapeutics presently has an average rating of “Buy” and an average price target of $34.07.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.